Search the Newsreel

ConocoPhillips awards Noble jackup rig a North Sea P&A contract

ConocoPhillips has awarded Noble Interceptor a 670-day plug-and-abandonment (P&A) contract in the Greater Ekofisk Area offshore Norway, starting in Q3 2027. This contract, valued for its long duration, strengthens Noble's presence in the North Sea P&A market and adds to a series of recent …

ConocoPhillips (NYSE:COP) Is About To Go Ex-Dividend, And It Pays A 2.7% Yield

ConocoPhillips (NYSE:COP) is set to go ex-dividend in the next two days, with shareholders needing to purchase shares before August 17th to be eligible for the US$0.84 per share dividend, yielding 2.7%. The company's dividend payments are considered sustainable as they are covered by …

Zenas BioPharma (ZBIO) Is Down 9.2% After Wider Losses And Leadership Changes - What's Changed

Zenas BioPharma reported widening losses in Q2 2026, with revenue dropping significantly year-over-year and net loss reaching US$111,460,000. These financial results were accompanied by leadership changes, including the CFO transitioning to a Strategic Advisor role and a new board appointment. The company's investment narrative …

Aspire BioPharma, Inc. (NASDAQ: ASBP) Share Price, ASBP Stock News, ASBP Share Price & Updates

Mereo BioPharma (MREO): EcoR1 reports 0.6% passive stake via ADS holdings

EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have reported a passive beneficial ownership of 0.6% each in Mereo BioPharma Group plc. This stake, held through American Depositary Shares (ADS), represents 5,000,000 Ordinary Shares for EcoR1 and Nodelman, and 4,732,750 Ordinary …

Immix Biopharma (NASDAQ:IMMX) Stock Price Down 4.5% - Here's Why

Immix Biopharma (NASDAQ: IMMX) shares dropped 4.5% to $10.43 on Friday, with trading volume significantly below average. This decline followed the company missing its latest quarterly earnings estimate, reporting a loss of $0.18 per share against an expected $0.17 loss. Despite the recent dip, …

Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Cue Biopharma reported its second-quarter 2026 financial results, highlighting a significant increase in revenue due to a collaboration milestone and higher expenses related to the CUE-221 development program. The company also announced the submission of an IND for CUE-221 in food allergy applications, a …

Immix Biopharma (IMMX) gains 5.6% stake holder led by Eventide Asset Management

Eventide Asset Management, LLC, through its Eventide Healthcare & Life Sciences Fund, has reported a beneficial ownership of 3,891,019 shares of Immix Biopharma (IMMX) common stock, representing a 5.6% stake. This Schedule 13G filing indicates that Eventide holds sole voting and dispositive power over …

Connect Biopharma (CNTB) investor Wei Zheng discloses 4% beneficial stake

Connect Biopharma Holdings Ltd (CNTB) investor Wei Zheng has filed an amended Schedule 13G, disclosing a beneficial ownership of 2,520,359 ordinary shares, which represents a 4% stake in the company. Zheng holds sole voting and dispositive power over these shares, with the percentage based …

GT Biopharma Q2 Results: Net Loss Falls To $4.5 Million

GT Biopharma (NASDAQ: GTBP) reported a Q2 2026 net loss of $4.5 million, a significant improvement from the $30.2 million loss in Q2 2025, primarily due to the absence of a non-recurring $28.7 million Greenshoe liability from the prior year. However, operational losses widened …

Theravance Biopharma (TBPH) investor group reports 17.7% beneficial stake

An investor group led by Madison Avenue International LP has reported a 17.7% beneficial stake in Theravance Biopharma, Inc. (TBPH) as of June 30, 2026. This ownership, comprising 9,212,252 Ordinary Shares, is based on 51,918,754 outstanding shares as of July 31, 2026. The group, …

Zenas BioPharma's (ZBIO) Buy Rating Reaffirmed at Guggenheim

Guggenheim reaffirmed its "buy" rating for Zenas BioPharma (ZBIO) with a $55 price target, despite the company reporting weaker-than-expected quarterly results, including an EPS loss of $1.77 and revenue of $1 million. Analyst sentiment for ZBIO remains generally positive with a "Moderate Buy" consensus …

Estrella Immunopharma (ESLA): Armistice Capital discloses 4.99% ownership stake

Armistice Capital, LLC and Steven Boyd have disclosed a 4.99% beneficial ownership stake in Estrella Immunopharma, Inc. (ESLA) common stock. This translates to 2,051,409 shares, over which they hold shared voting and dispositive power. The shares are held by Armistice Capital Master Fund Ltd., …

Quantum Biopharma Ltd. (CN:QNTM) Shares Decline as Biotech Uncertainty, Funding Risks and Clinical Development Challenges Pressure Investor Sentiment

Zenas BioPharma's (ZBIO) Outperform Rating Reiterated at Wedbush

Wedbush reiterated its "outperform" rating on Zenas BioPharma (NASDAQ:ZBIO) with a $45 price target, indicating a potential 54.11% upside. Despite this positive analyst sentiment, the company reported a significant miss on its quarterly earnings and revenue estimates. Other analysts have also adjusted their ratings, …

ConocoPhillips (COP): Wall Street Sees More Upside Despite Leadership Shakeup

ConocoPhillips (NYSE:COP) was held by 74 hedge fund investors at the end of Q1 2026 in the Insider Monkey database, with a total stake value of just over $7.5 billion. This is up from 65 hedge fund holders with a cumulative investment of almost …

GTBP: Q2 2026 net loss narrowed to $4.5M as clinical programs advance and cash runway extends to Q4 2026

GT Biopharma (GTBP) reported a narrowed net loss of $4.5 million in Q2 2026, a significant improvement from $30.2 million year-over-year, attributed to the absence of a prior non-recurring liability. The company is advancing two TriKE® candidates in Phase 1 trials, with updates anticipated …

Sutro Biopharma Q3 EPS Forecast Reduced by HC Wainwright

GT Biopharma (GTBP) cuts net loss but flags going concern and Nasdaq risk

GT Biopharma Reports Second Quarter 2026 Financial Results

GT Biopharma announced its second quarter 2026 financial results, highlighting ongoing Phase 1 trials for two TriKE® candidates, GTB-3650 and GTB-5550, with updates expected in the second half of 2026. The company reported a cash balance of $5.1 million, sufficient to fund operations through …

Driehaus Capital discloses 6.96% Cue Biopharma (CUE) holding in Schedule 13G

Driehaus Capital Management LLC has disclosed a 6.96% beneficial ownership stake in Cue Biopharma, Inc. (CUE), amounting to 292,144 shares. This holding is reported on a Schedule 13G filing, indicating a passive investment. The shares are held in fully discretionary accounts for investment advisory …

VOR|Vor Biopharma Inc|Price:23.260|Chg%:+0.920

Quantum BioPharma Says Cash Could Fund Plans to Oct. 2027

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX

Pomerantz LLP is investigating potential securities fraud claims against Immix Biopharma, Inc. (IMMX) following a significant drop in its stock price. The investigation stems from the company's termination of its Chief Medical Officer, Richard Graydon, who was later identified by media outlets as Ronald …

Citizens reiterates Immix Biopharma stock rating on pipeline progress

Citizens reiterated a "Market Outperform" rating and a $23.00 price target for Immix Biopharma (NASDAQ:IMMX), citing strong pipeline progress and potential for significant upside despite recent financial losses and an "overvalued" assessment by InvestingPro. The firm highlighted upcoming top-line results for NXC-201 in September …

ImmuneOnco Sets August Board Meeting to Approve Interim Results and Mull Dividend

Balyasny Asset Management (CBIO) discloses 6.03% Crescent Biopharma ownership

Balyasny Asset Management L.P. and its affiliated entities have reported a 6.03% beneficial ownership stake in Crescent Biopharma, Inc., totaling 1,662,917 shares of Class A common stock. This ownership is primarily held through Atlas Private Holdings (Cayman) Ltd. and Atlas Diversified Master Fund, Ltd. …

ConocoPhillips Starts Production at New Alaska Oil Project

ConocoPhillips has commenced production at its new Coyote 3SX project on Alaska's North Slope, which is expected to add up to 12,000 barrels per day. The project was completed ahead of schedule and under budget at approximately $800 million, and its production will be …

Cyclopharm (ASX:CYC) Records Revenue Growth While US Technegas Rollout Progresses

ConocoPhillips (NYSE:COP) Receives Consensus Rating of "Moderate Buy" from Analysts

ConocoPhillips (NYSE:COP) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $137.68. The company recently surpassed earnings expectations, reporting $3.24 EPS against a $2.90 consensus and $19.52 billion in revenue. ConocoPhillips also declared a quarterly dividend of …

Karyopharm Q2 Net Loss Expands; Reaffirms 2026 Revenue Guidance; Plans SNDA For Selinexor In August

(RTTNews) - Karyopharm Therapeutics Inc. (KPTI), a commercial-stage pharmaceutical company, reported financial results for the second quarter of 2026, reflecting a wider net loss and provided an update on the company's myelofibrosis program. In addition, the company reaffirmed the full-year 2026 revenue guidance. Karyopharm, …

Form 8K Dawson Geophysical Company For: 13 August By Investing.com

This article reports on Dawson Geophysical Company's Form 8K filing for August 13. It is a brief announcement from Investing.com, providing no further details about the content of the Form 8K. The article also includes stock performance data for Dawson Geophysical Company (DWSN).

Argent BioPharma (ASX:RGT): CannEpil Licence Expansion Adds Veterinary Royalty Opportunity

Truist Financial Keeps Their Hold Rating on Conocophillips (COP)

Cue Biopharma, Inc. SEC Filing (Aug 14, 2026)

This article reports on a Form 144 SEC filing by Cue Biopharma, Inc. (CUE) on August 14, 2026. The filing indicates a proposed sale of 8,829 shares of common stock with an aggregate market value of $266,106.06, acquired through Restricted Stock Units vesting under …

Quantinuum (QNTM) Stock Wrestles With IPO Charge After Revenue Jump